Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07427498 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Role of Priors in Hallucinatory Perception in Parkinson's Disease

Study acronym: LEAP-PARK
StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Recruitment opened Show 7 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Primary completion moved earlier from Oct 2028 to Apr 27, 2028
    • Study completion moved earlier from Nov 2028 to Apr 27, 2028
    • Study sites: 1 to 2
    • Start date changed from estimate of Mar 2026 to Apr 28, 2026
    • Eligibility criteria expanded, about 7 words
    • Secondary endpoints: details revised at 4 of 4 entries
  2. Study description shortened, about 3 words
    • Study title shortened, about 4 words
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this observational study is to better understand the mechanisms of hallucinations in patients with Parkinson's disease. The main question it aims to answer is: Do prior expectations increase the rate of false perceptions during a visual stimulus detection task more in Parkinson's disease patients with visual hallucinations compared to those without? Participants will undertake a computer task involving face detection and a battery of neuropsychological tests.
Trial Details
NCT Number NCT07427498
Lead Sponsor University Hospital, Grenoble
Collaborators: INSERM U1216 Grenoble Institut des Neurosciences
Conditions
(from sponsor)		 PARKINSON DISEASE (Disorder)
Related terms Hallucinations, Parkinson Disease
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov